Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth
Published . Updated .
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth Morningstar
Directly affected
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth Morningstar
Source: Morningstar
The price since 13 Oct 2026: Acadia Healthcare (ACHC) versus the S&P 500
Since the first closing price after “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” Acadia Healthcare (ACHC) is -4.55%. The S&P 500 fund (SPY) is -0.40% over the same days, a -4.15% difference versus the market.
| Company | When | Move | Status |
|---|---|---|---|
| Acadia Healthcare (ACHC) | that day | +0.50% | final price |
| Acadia Healthcare (ACHC) | the next day | +5.29% | final price |
| Acadia Healthcare (ACHC) | two days later | +3.19% | final price |
| Acadia Healthcare (ACHC) | three days later | -0.33% | final price |
| Acadia Healthcare (ACHC) | three days earlier | -5.32% | final price |
| Acadia Healthcare (ACHC) | five days earlier | -3.46% | final price |
| Ascendis Pharma A/S (ASND) | that day | -1.62% | final price |
| Ascendis Pharma A/S (ASND) | the next day | +0.04% | final price |
| Ascendis Pharma A/S (ASND) | two days later | -0.14% | final price |
| Ascendis Pharma A/S (ASND) | three days later | -0.76% | final price |
| Ascendis Pharma A/S (ASND) | three days earlier | -1.88% | final price |
| Ascendis Pharma A/S (ASND) | five days earlier | -0.35% | final price |
| aTYR PHARMA (ATYR) | that day | -7.79% | final price |
| aTYR PHARMA (ATYR) | the next day | -16.23% | final price |
| aTYR PHARMA (ATYR) | two days later | -14.52% | final price |
| aTYR PHARMA (ATYR) | three days later | -18.17% | final price |
| aTYR PHARMA (ATYR) | three days earlier | +18.40% | final price |
| aTYR PHARMA (ATYR) | five days earlier | +30.15% | final price |
| BridgeBio Pharma (BBIO) | that day | -3.73% | final price |
| BridgeBio Pharma (BBIO) | the next day | -1.23% | final price |
| BridgeBio Pharma (BBIO) | two days later | +2.10% | final price |
| BridgeBio Pharma (BBIO) | three days later | +0.97% | final price |
| BridgeBio Pharma (BBIO) | three days earlier | -1.08% | final price |
| BridgeBio Pharma (BBIO) | five days earlier | +1.84% | final price |
| Davita (DVA) | that day | +0.34% | final price |
| Davita (DVA) | the next day | -0.54% | final price |
| Davita (DVA) | two days later | +4.08% | final price |
| Davita (DVA) | three days later | +2.99% | final price |
| Davita (DVA) | three days earlier | -2.48% | final price |
| Davita (DVA) | five days earlier | -0.74% | final price |
Official trades in Acadia Healthcare (ACHC) around 13 Oct 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 14 days before publication, inside 30 days. The filing is listed beside the story “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 32 days before publication, inside 60 days. The filing is listed beside the story “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies carried with this story
- ACHC Acadia Healthcare
For “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
On 13 Oct 2026, “Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth” is the story that connects Acadia Healthcare (ACHC) to this story.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Ascendis Pharma A/S (ASND): GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
What the saved facts support for Acadia Healthcare (ACHC)
46 out of 100
“Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.